We know from experience that the barriers to access care are
complex: from getting the product to those who need it – at a price
they can afford and with a reliability they can depend on, to
combatting shortages of healthcare professionals who can effectively
diagnose and treat diabetes with the required equipment.
Through a growing range of programmes and partnerships, we continue to expand our efforts and creating solutions to help people access the diabetes care they need, no matter where they live.
The Changing Diabetes® in Children programme ensures care and life-saving insulin for children with type 1 diabetes in low- and middle-income countries. Working together with Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF), we have established 177 clinics in 14 countries. Today, Changing Diabetes® in Children is providing medical care and insulin to nearly 20,000 children.
In 2018, we established a
ground-breaking partnership with the International
Committee of the Red Cross , the Danish Red Cross to tackle the growing need
to improve chronic disease treatment. Our joint effort is anchored
in a collective vision that all people living in humanitarian crises
should have access to the healthcare they need.
In 2018, the Defeat-NCD Partnership was established to support
countries’ efforts to both prevent and treat chronic disease. The
public–private–people partnership is hosted by the United Nations
Office for Project Services (UNOPS) and includes governments,
multilateral agencies, civil society, academia, philanthropic
foundations and the private sector.
For many of these patients, living with diabetes becomes a daily struggle to cover the cost of treatment and basic necessities like housing, food and transportation.
Our Base of the Pyramid programme aims to ease the cost burden related to both medicines and healthcare. Initiated in 2010, the programme is working through local health authorities and health care organisations in four African countries.
PHOTO: PATH / Eric Becker
Since 2014, we have been
working with PATH to better understand and
remove the barriers to affordable essential medicines and
technologies for diabetes in low- and middle-income countries.
Haemophilia is a hereditary bleeding disorder affecting one in 10,000 people.1 75% of people with haemophilia live in the developing world, where most do not have a diagnosis or access to adequate care.